A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome

Trial Profile

A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Micafungin (Primary) ; Posaconazole (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2017 New trial record
    • 08 Oct 2017 Results assessing effect of micafungin versus posaconazole prophylaxis in patients with acute leukemia or myelodysplastic syndrome, were presented at the IDWeek 2017.
    • 04 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top